GLP-1 drugs such as Wegovy and Ozempic have been revolutionary for obesity and type 2 diabetes treatments, but questions remain about some of the side effects and potential negative impacts of these medications.

The study looked at 50,000 people on the drugs

The use of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity is associated with an increased risk of hair loss (alopecia) in adults with type…